(RTTNews) - GH Research PLC (GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, announced ...

In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in ...

In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana, psychedelics are ...

Tuesday, GH Research PLC (NASDAQ:GHRS) received a reiterated Buy rating and $40.00 price target from H.C. Wainwright, representing significant upside potential for the $936... On Monday, Rodman ...

In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other small cap stocks. On February 14, Stacey Sears, portfolio manager at Emerald Advisors ...

Shares of GHRS stock opened at $11.00 on Thursday. The firm’s 50-day moving average is $11.13 and its 200-day moving average is $9.18. The stock has a market cap of $572.31 million, a price-to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...